Affecting approximately 1 percent of the population, VWD is a common inherited bleeding disorder that occurs when the blood lacks a protein that helps clotting.
HOBOKEN, N.J.--(BUSINESS WIRE)-- Octapharma USA, Inc. sponsored the recently completed VWD Connect Foundation’s National Type 3/Severe Von Willebrand Disease (VWD) Conference, a four-day national program, held for the third consecutive year.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190710005202/en/
Pictured (from left) at the recently completed VWD Connect Foundation’s national conference, sponsored by Octapharma USA, are: Tung Wynn, MD, Hemophilia Treatment Center, UF Health Shands Children’s Hospital, Gainesville, FL; Robert Montgomery, MD, Blood Research Institute and Medical College of Wisconsin, Milwaulkee, WI; Bruce Schwartz, PhD, Octapharma; Azim Saifee, Octapharma; Ed Kuebler, MSW, LLC, VWDConnect Foundation; Jeanette Cesta, VWDConnect Foundation; Rich Walters, Octapharma; Tabetha McGlinchey, Octapharma; Alice Anderson, PT, DPT, PCS, Children’s Health, Dallas, TX; and Christopher Walsh, MD, The Mt. Sinai Hospital, New York, NY. (Photo: Business Wire)
“Octapharma has helped us make this conference a reality since its inception,” said VWD Connect Foundation Executive Director Jeanette Cesta. “The conference continues to be an outstanding opportunity to offer patients and their guests the latest insights from leading physicians and medical professionals on Type 3/severe VWD. Patients tell us every year that they are making lasting connections with people in the bleeding disorders community and developing friendships that help them meet life’s daily challenges.”
Affecting approximately 1 percent of the population, VWD is a common inherited bleeding disorder that occurs when the blood lacks a protein that helps clotting. Type 3 VWD is the rarest and most severe form of the condition, representing approximately 5% of cases, according to the National Organization for Rare Disorders.
“It is important that we continue to bring awareness to Von Willebrand Disease and the unique challenges patients encounter,” said Octapharma USA President Flemming Nielsen. “Octapharma has supported this great conference for three straight years because we are committed to helping patients get the most out of life. Unique educational and relationship-building initiatives help patients be the best version of themselves and we are honored to be a part of that process.”
Educational information and other resources were provided on various medical issues, such as treatment alternatives, joint health, symptoms and diagnosis. Emotional and social topics on the agenda included family and professional relationships, challenges of loss and depression, disclosure issues, and positive coping strategies.
Physicians, healthcare providers specializing in bleeding disorders, geneticists, health educators, nurses, physical therapists, and social workers were among the many professional resources available to conference attendees. For complete conference information, please visit www.VWDConnect.org.
About the VWD Connect Foundation
VWD Connect Foundation is a Florida-based 501(c)3 non-profit organization created to serve the bleeding disorder community, focusing on severe von Willebrand Disease. It provides education and connection for patients and families, and supports research that will benefit the von Willebrand Disease community.
About the Octapharma Group
Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein products manufacturers in the world and has been committed to patient care and medical innovation since 1983. Its core business is the development and production of human proteins from human plasma and human cell lines. Octapharma employs approximately 8,314 people worldwide to support the treatment of patients in over 115 countries with products across the following therapeutic areas: Hematology (coagulation disorders), Immunotherapy (immune disorders) and Critical Care. The company’s American subsidiary, Octapharma USA, is located in Hoboken, N.J. Octapharma operates three state-of-the-art production sites licensed by the U.S. Food and Drug Administration (FDA), providing a high level of production flexibility. For more information, please visit www.octapharmausa.com.
WIL-0213
Octapharma USA, Inc.• 121 River Street, Suite 1201• Hoboken, NJ 07030 • 201-604-1130 • www.octapharmausa.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190710005202/en/
Source: Octapharma USA
Smart Multimedia Gallery
Pictured (from left) at the recently completed VWD Connect Foundation’s national conference, sponsored by Octapharma USA, are: Tung Wynn, MD, Hemophilia Treatment Center, UF Health Shands Children’s Hospital, Gainesville, FL; Robert Montgomery, MD, Blood Research Institute and Medical College of Wisconsin, Milwaulkee, WI; Bruce Schwartz, PhD, Octapharma; Azim Saifee, Octapharma; Ed Kuebler, MSW, LLC, VWDConnect Foundation; Jeanette Cesta, VWDConnect Foundation; Rich Walters, Octapharma; Tabetha McGlinchey, Octapharma; Alice Anderson, PT, DPT, PCS, Children’s Health, Dallas, TX; and Christopher Walsh, MD, The Mt. Sinai Hospital, New York, NY. (Photo: Business Wire)
View this news release and multimedia online at:
http://www.businesswire.com/news/home/20190710005202/en
